Press Release
The C. DIFF QUIK CHEK COMPLETE® test from TECHLAB, Inc., part of the SSI Diagnostica Group, receives the first* European IVDR Certification for combined GDH plus Toxin A/B test… Continue reading
- Home
- Author: TECHLAB®
About TECHLAB®
TECHLAB®, Inc. develops, manufactures, and distributes rapid non-invasive intestinal diagnostics in the areas of intestinal inflammation, antibiotic associated diarrhea and parasitology.
2 Steps Are Better Than 1 for CDI Testing
Independent research presented at the 2023 European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2023) shows that, when compared to a one-step algorithm of polymerase chain reaction (PCR) testing alone, a two-step C. difficile algorithm including… Continue reading
TECHLAB recognized as one of the “2022 Best New Partners”
TECHLAB is proud to be recognized as one of the “2022 Best New Partners” at the Fisher Healthcare Supplier Awards Meeting. Thank you for your partnership and we look forward to continued success in … Continue reading
C. diff RT151 was not detected by a commercially available molecular assay
Read more here: https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(22)00606-1/fulltext… Continue reading
SSI Diagnostica continues strong growth journey by merging with Virginia-based TECHLAB
SSI Diagnostica Group (SSID), a global in-vitro diagnostics company backed by Adelis Equity Partners, has experienced significant growth in recent years based on its ability for new product innovation, expansion into international markets and strategic acquisitions. SSID’s latest transformational acquisition is the Virginia-based firm TechLab, Inc., a leading developer and manufacturer of rapid infectious disease … Continue reading
Characterization of Clostridioides difficile Strains from an Outbreak Using MALDI-TOF Mass Spectrometry
A recent study in Microorganisms reports the first case of a C. difficile tcdA+/tcdB– outbreak strain. This C. difficile strain has a functional copy of the Toxin A gene (tcdA) that produces Toxin A but contains a mutation in the Toxin B gene (tcdB), limiting the ability to detect infections by molecular tests that target the tcdB region to detect infection. Click here to view the article. … Continue reading
The Microbiome and Recurrent Clostridioides difficile
Listen to The Microbiome and Recurrent Clostridioides difficile: Trust Your Gut (medscape.org), a CME accredited webinar led by Dr. Feuerstadt, Dr. Oneto, and Dr. Khanna, which discusses the burden of recurrent C. difficile infections (CDI) on patients & healthcare facilities. Patients with inflammatory bowel disease (IBD) who may be experiencing a flare should be tested for C. diff. A toxin-based … Continue reading
The Importance of C. difficile Toxin Testing.
Dr. David Lyerly spoke at the Peggy Lillis Foundation 2022 National C. diff Advocacy Summit in Washington D.C. about the importance of C. difficile toxin testing. A synopsis of his talk can be found on Medscape. … Continue reading
Clostridioides difficile in inflammatory bowel disease
Clostridioides difficile (CDI) and Inflammatory Bowel Disease (IBD) present similar clinical features, but require very different therapies. Because CDI and C. difficile carriage are both common in IBD patients, diagnosis can be challenging. Read more in the March issue of … Continue reading
Why Stool Antigen Testing Outperforms Serology in Identifying H. pylori
Half the world’s population is seropositive for H. pylori, but may not have a current infection. Stool antigen testing provides clinically relevant results. Read more about H. pylori testing and guideline recommendations in this article, published in CLP. Why Stool Antigen Testing Outperforms Serology in Identifying H. pylor… Continue reading